LESLIE A COTTO
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism WELLINGTON, FL NPI 1609167659
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism FL Lilly USA, LLC All categories
General Payments — all program years on this page
$14,120.19
- Category: General Payments
- Program years: PY2018–2024
- Record count: 754
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,862.30 across 134 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,862.30 | 134 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $368.58 | 24 |
| Novo Nordisk AS | $259.48 | 16 |
| Amgen Inc. | $230.45 | 9 |
| SANOFI-AVENTIS U.S. LLC | $216.15 | 9 |
| BETA BIONICS, INC. | $214.68 | 4 |
| DEXCOM, INC. | $181.52 | 10 |
| MannKind Corporation | $171.71 | 9 |
| Tandem Diabetes Care, Inc. | $133.62 | 3 |
| RECORDATI_RARE_DISEASES_INC. | $132.06 | 5 |
| Antares Pharma, Inc. | $102.61 | 5 |
| Bayer HealthCare Pharmaceuticals Inc. | $99.37 | 4 |
| Radius Health, Inc. | $97.87 | 4 |
| Insulet Corporation | $96.45 | 4 |
| Corcept Therapeutics | $76.15 | 4 |
| Amneal Pharmaceuticals LLC | $70.06 | 4 |
| Alexion Pharmaceuticals, Inc. | $53.85 | 2 |
| ABBVIE INC. | $48.70 | 2 |
| Xeris Pharmaceuticals, Inc. | $48.10 | 2 |
| Abbott Laboratories | $35.90 | 2 |
| VIVUS LLC | $34.62 | 2 |
| Kyowa Kirin, Inc. | $25.28 | 1 |
| Neurocrine BioSciences, Inc. | $25.05 | 1 |
| PFIZER INC. | $23.72 | 1 |
| CeQur Corporation | $21.80 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.21 | 1 |
| Alvogen Inc | $18.03 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $16.92 | 1 |
| Esperion Therapeutics, Inc. | $14.27 | 1 |
| Acella Pharmaceuticals, LLC | $13.90 | 1 |
| Medtronic, Inc. | $13.19 | 1 |
By program year
Records — PY2024 (134)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.